BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
7 results:

  • 1. Disparities Associated with Shared Decision-making in prostate cancer Screening.
    Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H
    Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Post-transcriptional modification of m
    Li Y; Zhu S; Chen Y; Ma Q; Kan D; Yu W; Zhang B; Chen X; Wei W; Shao Y; Wang K; Zhang M; Deng S; Niu Y; Shang Z
    Cell Death Dis; 2023 Apr; 14(4):289. PubMed ID: 37095108
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis.
    Gao Y; Ha YS; Kwon TG; Cho YC; Lee S; Lee JN
    Cancer Genomics Proteomics; 2020; 17(5):543-553. PubMed ID: 32859632
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2018 Nov; 129(2):370-376. PubMed ID: 30190166
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer.
    Amatangelo MD; Goodyear S; Varma D; Stearns ME
    Carcinogenesis; 2012 Oct; 33(10):1965-75. PubMed ID: 22791812
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway.
    Su B; Bu Y; Engelberg D; Gelman IH
    J Biol Chem; 2010 Feb; 285(7):4578-86. PubMed ID: 20018890
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Patient time costs associated with cancer care.
    Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
    J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.